Spinal and bulbar muscular atrophy (SBMA), or Kennedy's disease, is a late onset motor neuron disease (MND) caused by an abnormal expansion of the CAG repeat in the androgen receptor (AR) gene on the X-chromosome, encoding a polyglutamine sequence (poly-Q) in the protein product. Mutant poly-Q expanded AR protein is widely expressed but leads to selective lower motoneuron death. Although the mechanisms that underlie SBMA remain unclear, defective axonal transport has been implicated in MND and other forms of poly-Q disease. Transcriptional dysregulation may also be involved in poly-Q repeat pathology. We therefore examined axonal transport in a mouse model of SBMA recapitulating many aspects of the human disease. We found no difference in the expression levels of motor and the microtubule associated protein tau, in spinal cord and sciatic nerve of wild-type (WT) and SBMA mice at various stages of disease progression.
Introduction
Spinal and bulbar muscular atrophy (SBMA), otherwise known as Kennedy's disease, is a hereditary neurodegenerative X-linked disorder which arises from an expansion of the CAG repeat in the first exon of the androgen receptor (AR) gene encoding a polyglutamine (poly-Q) stretch in the translated protein (1) . It belongs to a family of poly-Q repeat disorders which includes Huntington's disease (HD) (2) . SBMA primarily affects males who experience progressive bulbar dysfunction and proximal limb muscle atrophy and weakness. In the normal population the polymorphic CAG repeat ranges from 9-36 and an expansion of greater than 38 residues results in disease (3) . Mutant expanded AR protein is ubiquitously expressed but leads to selective lower motoneuron loss in the spinal cord and bulbar nuclei of the brainstem. Although the cause of the motoneuron death and dysfunction in SBMA, which is restricted to particular lower and bulbar motoneurons, is largely unknown, current evidence supports the involvement of axonal transport dysfunction and transcriptional dysregulation (4, 5) . Motoneurons, by virtue of their very long axons, are particularly vulnerable to axonal transport defects and disturbances have been observed even in embryonic motoneurons in mouse models of Amyotrophic lateral sclerosis (ALS), the most common form of adult Motor Neuron 4 complex, causes a slowly progressive form of MND, possibly by disrupting the binding of dynactin to microtubules and thereby impairing axonal retrograde transport (8) . In addition, in sporadic ALS patients, mRNA levels of dynactin 1 are reduced (9) , signifying the importance of diminished levels of axonal transport proteins in MND pathology.
In the context of SBMA, transcriptional dysregulation by mutant AR has also been shown to decrease p150
Glued in a mouse model of SBMA (10) . Several in vitro studies using squid axon models in which mutant expanded AR and poly-Q proteins are overexpressed, have also reported deficits in axonal transport (11) (12) (13) , which are caused by a loss of kinesin binding (14) . In vivo, axonal transport deficits have been detected using fluoro-gold tracer analysis in a mouse model of SBMA, likely to be the result of transcriptional-dependent loss of p150 Glued (10) . However, over-expression of mutant AR in these mice does not result in motoneuron degeneration but instead manifests in an abrupt development of muscle pathology leading to premature death, which is unlike the course and pattern of the disease observed in humans (15) . The mouse model used in this study, in which the mutant AR is expressed at endogenous levels, follows more accurately the course of disease seen in humans, resulting in significant motoneuron loss leading to a progressive late-onset neuromuscular phenotype (4) . The male mice carry the expanded 100 poly-Q AR repeat mutation (pathogenic AR100 mice) or 20 poly-Q AR repeats (non-pathogenic AR20 mice), which do not possess any phenotype, as less than 38 poly-Q repeats in humans does not cause disease.
Given that transcriptional dysregulation by mutant AR may result in alteration of protein levels, which could account for any transport deficit, in this study we set out to examine in detail the expression of axonal transport-related proteins in a SBMA transgenic mouse model which recapitulates the natural history of the human disease more closely (4).
Furthermore, we determined the binding efficiency of motor complexes and the microtubule associated protein tau, to test the hypothesis that their uncoupling may lead to destabilisation and/or transport disturbances. Additionally, we investigated the role of axonal transport kinetics in motoneurons both in vitro and in vivo, which allowed us to fully characterise the involvement of axonal transport deficits in SBMA mice. We demonstrate both through biochemical and transport assays in living neurons, that axonal transport is not compromised in SBMA transgenic mice (4). Collectively, our observations suggest that unlike several other motor and poly-Q disorders, the underlying pathology in SBMA may not be due to an impairment in axonal transport. Therefore the development of therapeutic strategies for SBMA would be better focused on alternative targets.
Results

Mutant androgen receptor expression results in motoneuron degeneration in SBMA mice
The SBMA mouse model has been previously characterised (4) and mice heterozygous for the expanded AR100 mutation (100 poly-Q AR repeats) have been shown to develop a late-onset, gender specific, progressive muscular phenotype similar to the disease manifested in human SBMA patients. The mice exhibit a motor phenotype and show clear histological evidence of muscle pathology in hindlimb muscles (4) . Nonetheless, quantitative analysis of motoneuron number and loss in the spinal cord has not been previously described for these mice. As the disease is gender specific, in this study we examined heterozygous male mice with the expanded AR100 (pathogenic) poly-Q tract which develop histopathological changes in muscle and spinal cord, consistent with a late-onset neuromuscular phenotype (4). Additionally, heterozygote male AR20 mice, which carry non-pathogenic 20 poly-Q AR repeats and do not develop a phenotype, were compared to the AR100 mice. To further characterise the pathology in the mutant AR mice, we show that as well as the histopathological alterations shown by Sopher et al (4), staining of lumbar spinal cord sections reveal that motoneuron survival in the sciatic motor pool (Fig 1A, encircled area) was significantly compromised in the mutant expanded AR100 but not in WT or AR20 mice (Fig 1A, B) . In mutant AR100 mice the total number of surviving motoneurons was only 226.22 (± 13.37, n=8) in 18 month old 7 mice compared to 365.80 (± 10.91, n=7) in AR20 control mice and 386.37 (± 7.51, n=7; p < 0.001 ANOVA, Fig 1B) in WT mice. The AR100 mice therefore develop a neuromuscular pathology characterised by loss of approximately 40% of motoneurons in the sciatic motor pool of the lumbar spinal cord by 18 months of age. The natural history of neurodegeneration in these mice therefore, more closely resembles the observations in humans, compared to other reported SBMA models (15) .
The expression levels of axonal transport proteins are not altered in SBMA mice
In MND, it is now well documented that impairment in axonal transport is an early feature of disease and has been observed in motoneurons of SOD1 mice that model ALS, both in vitro in isolated embryonic motoneurons (7) and in vivo in intact adult sciatic nerves at different disease stages (6, 16) . We therefore set out to examine the role of axonal transport in a SBMA mouse model. Since deficits in axonal transport may arise from a decrease in levels of transport related proteins, we examined the expression levels of these proteins in SBMA mice in which mutant expanded poly-Q AR100 is associated with transcriptional dysregulation (4) . Levels of the motor proteins (kinesin 1, cytoplasmic dynein), tau, a microtubule-stabilizing protein and a regulator of axonal transport (17) and the dynein-associated protein p150 Glued were established in presymptomatic (3 months), symptomatic (12 months) and diseased mice near endstage (18 months) and the results are summarised in Fig 2 and Fig 3. Protein levels were assessed in WT, AR20 and AR100 poly-Q male mice in the spinal cord (Fig 2) and sciatic nerve (Fig 3) , two primary regions displaying SBMA pathology. Our findings
show that there was no alteration in levels of axonal transport related proteins, at any stage of the disease process, in either the spinal cord or sciatic nerve of mutant mice. At 18 months (Fig 2C) , there was a general but small decline in the levels of protein examined in spinal cord in AR100 mice. However, statistical analysis and pairwise comparisons between all genotypes showed there were no statistically significant differences in the expression level of any of the proteins. This general decline in the expression levels of all the examined proteins, observed in 18 month spinal cord, is likely to be a reflection of the significant loss of motoneurons that has occurred by this stage of the disease (Fig 1) . These results show that the transcriptional dysregulation induced by the mutant AR100 does not impact on the levels of proteins involved in axonal transport. In view of these findings, we next examined axonal transport in motoneurons of developing and adult SBMA mice.
Microtubule binding efficiency of motor complexes and tau in SBMA mice
Kinetics of retrograde axonal transport of TeNT H C in cultured motor neurons from
SBMA mice
Axonal transport deficits are one of the earliest deficits to have been identified in ALS in embryonic motoneurons (7) . In addition, deficits in axonal transport have also been implicated in the pathogenesis of SBMA (10, 13, 14) . Therefore, in conjunction with the biochemical analysis shown above, we set out to examine axonal transport kinetics in littermates were treated with androgen receptor agonist (DHT) before transport assays were performed (Fig 6) . The results showed that there was no significant difference between WT and mutant AR100 mice when the speed of carriers (Fig 6A) , proportion of carriers pausing (Fig 6B) and the proportion of carriers that pause per axon (Fig 6C) were measured. Taken together, these findings show that the mutant AR100 does not disrupt axonal transport kinetics in embryonic motoneurons.
Retrograde transport is unaffected in adult SBMA mice in vivo
Since SBMA is a progressive late onset neurodegenerative disorder, it is possible that deficits in axonal transport may only manifest in adult motoneurons. We therefore examined axonal transport in vivo in anaesthetised adult SBMA mice. Following intramuscular injection of fluorescently-labelled TeNT H C in both 13 month-old WT and heterozygous AR100 mice, we were able to monitor its axonal transport in the intact sciatic nerve (16) . In vivo transport of TeNT H C occurred predominantly in the retrograde direction in the sciatic nerve (Fig 7A) , as previously described (16), with very rare anterograde movements. Quantitative and statistical analysis of the retrograde transport of these carriers in vivo in single axons revealed no significant difference between the heterozygous AR100 mice and their age matched WT littermates (Fig 7B) .
Taken together, our results therefore show that retrograde transport is not altered in motoneurons at any stage of disease progression in AR100 mice that model SBMA.
Discussion
Failure in the transport of vital cargoes and nutrients along axons has been shown to arise early in ALS (7, 27) . In addition, expanded poly-Q mutant proteins have also been reported to disrupt axonal transport in several models of poly-Q diseases (10, 13, 14) . In this study we therefore set out to investigate the role that axonal transport may play in the pathology of SBMA. Our findings show that in SBMA mice, there was no change in the expression levels of components of the axonal transport machinery in either the spinal cord or sciatic nerve at any stage of the disease. Furthermore, changes in the microtubule binding properties of motor proteins and tau, which might have caused deficits in axonal transport, were also not observed in SBMA mice. Accordingly, functional analysis of axonal transport kinetics both in vitro in developing embryonic motoneurons and in vivo in adult symptomatic mice, confirmed that axonal transport was not impaired in mutant SBMA mice. Therefore, our results show that, contrary to other neurodegenerative diseases such as ALS, Alzheimer's disease and HD, there is no evidence that impaired axonal transport plays a significant role in the initiation or progression of SBMA.
The role of axonal transport deficits in motoneuron disorders have been extensively studied (6, 7, 16, (28) (29) (30) (31) . Motoneurons are particularly dependent for their survival and function on an efficient bidirectional transport system for important cargoes including mitochondria, vesicles and nutrients. Deficits in axonal transport have been shown to be one of the very earliest pathogenic manifestations of disease in ALS mutant SOD1 embryonic motoneurons (7) and have also been observed in vivo in motoneurons of adult SOD1 mice prior to symptom onset (6, 16) . Studies in ALS patients (32) and transgenic mouse models (7, 16, 27, (32) (33) (34) (35) confirm that impairments of axonal transport occur in both retrograde and anterograde directions. Moreover, the presence of transport deficits in mutant SOD1 motoneurons during embryonic development (7, 27) and at presymptomatic stages of disease (16) suggest that these deficits may play a causative role in disease initiation in ALS.
In HD, a poly-Q disease similar to SBMA, expression of full-length mutant huntingtin (Htt) has been shown to impair axonal transport in embryonic neurons both in vitro, by measurement of vesicle motility, and in vivo, by use of the retrograde tracer fluoro-gold (36) . In view of the studies concluding that in neurodegenerative disorders, pathology is secondary to disruption of transport (7, 16, 36, 37) , we initially hypothesised that axonal transport disturbances would be observed in SBMA mice. Indeed, several studies have previously suggested the involvement of axonal transport deficits in SBMA in vitro.
Expanded AR added to squid axoplasm preparations inhibits fast axonal transport (13) via a mechanism thought to involve the inhibition of kinesin binding to microtubules (14, 38) . Neuropil aggregate formation in mutant AR transfected NSC34 cells, lead to alteration of axonal trafficking and mitochondrial distribution in cell processes (11) . Earlier evidence therefore argues that axonal transport deficits may be involved in the pathology of SBMA. In this study however, using several biochemical and transport assays, we found no impairment in transport in SBMA mice. There was no decrease in the expression levels of axonal transport proteins, nor a significant impairment of their microtubule binding. We did however observe a minor alteration in the binding of DIC in the spinal cord of 18 month old AR100 mice at advanced stages of the disease. However, this is unlikely to be a primary factor in SBMA pathogenesis, and is more likely to arise as a consequence of the disease.
Measurement of transport kinetics verified that axonal transport rates were not compromised in SBMA mice, despite the mice displaying the characteristic pathology of lower motoneuron degeneration associated with a neuromuscular phenotype. These results were surprising, since SBMA is both a MND and a poly-Q disease. However, unlike in HD, the affected protein is not normally involved in intracellular transport. Htt assists in the transport of BDNF-containing vesicles (39) , and interacts with dynein and htt-associated protein-1 (HAP1), which complexes with p150 Glued and kinesin 1 (39-41).
In This strain develops an unusually rapid neuromuscular phenotype in the absence of motoneuron degeneration, resulting in a reduced life span. This is in contrast to the human disease, where SBMA is a disease of the middle age involving loss of lower motoneurons and a slowly progressive natural history with motor disability, but rarely associated with early mortality (15) . Importantly, a characteristic and defining pathological feature of SBMA is the loss of motoneurons, which is fundamental to the development of disease (43) . The YAC transgenic mice used in the present study (4), develop a late-onset progressive muscular phenotype similar to that observed in human SBMA patients, associated with a significant loss of motoneurons from the sciatic motor (Fig 1) . In addition, the expression patterns and levels of the AR expressed in this model recapitulate the endogenous gene expression of the AR (4). As a result, this mouse model represents an excellent genetic reproduction of SBMA (44).
In conclusion, in this study we provide evidence that there is no disruption of axonal transport in a well characterised mouse model of SBMA, which reproduces key features and natural history of the human disease more accurately. Although SBMA shares many features with other MND and poly-Q diseases, our findings indicate that compromised axonal transport is not a pathological feature of SBMA. Our results therefore challenge the view that the pathogenesis of SBMA involves deficits in axonal transport. These data suggest that alternative disease mechanisms and molecular targets for potential therapies in SBMA need to be identified. To maintain the colony, heterozygote males carrying the 100 poly-Q AR repeats (pathogenic AR100 mice) or 20 poly-Q AR repeats (non-pathogenic AR20 mice) were mated with wild-type (WT) C57BL6J females. Only male offspring were used for all experiments to ensure gender specificity of the disease and all AR mutant mice (AR20 and AR100) were heterozygote for the mutation. Genotyping of mice was carried out by PCR amplification on ear punches on weaned animals and repeated on tail snips on completion of all experiments, using a forward (5'-catctgagtccaggggaacagc-3') and reverse primer (5'-gcccaggcgctgccgtagtcc-3') with digestion of the PCR product with Bgl1 (New England Biolabs, UK). To collect tissue, mice were terminally anaesthetised with phenobarbitone, transcardially perfused with 0.9 % saline and whole spinal cord and sciatic nerves were rapidly dissected, snap frozen in liquid nitrogen and stored at -80°C.
Materials and Methods
Materials
Microtubule binding assay
Microtubules from spinal cord and sciatic nerve were isolated from WT and mutant AR mice and a microtubule binding assay performed as described (46) . 
Western blot analysis
Protein levels were determined using western blotting as described (47) . Proteins were separated by SDS-PAGE, transferred onto nitrocellulose membrane, incubated with indicated primary antibodies followed by either anti-mouse AlexaFluor 680 (Invitrogen, Paisley, UK) or anti-rabbit IR dye 800 (Rocklard, UK) secondary antibodies. Blots were examined using the Odyssey detection system (Licor, UK) and densitometry was performed using the Odyssey software. For the microtubule binding assay, densitometry values of bands in the fractions were normalized to tubulin levels in each fraction, which were subsequently normalized to tubulin levels in the total protein lysates (the input material used for generating microtubule fractions).
Motoneuron Cultures
Mixed primary motoneuron cultures were prepared from WT and AR100 mice as previously described (48) . Spinal cords from E13 embryonic mice were removed, ventral horns isolated and tissue dissociated with 0.025% trypsin. Motoneurons were plated onto poly-ornithine and laminin coated plates and cells were grown in neurobasal medium supplemented with 2% B27 supplement, 0.5 mM glutamine, 0.05% mercaptoethanol and 2% horse serum (all Invitrogen, Paisley, UK), 0.1 ng/mL glial derived neurotrophic factor (GDNF), 0.5 ng/mL ciliary neurotrophic factor (CNTF) and 0.1 ng/mL brain derived neurotrophic factor (BDNF) (all Caltag, Silverstone, UK), 50 U/mL penicillin, 50 µg/mL streptomycin (all Sigma-Aldrich, Poole, UK). Motoneurons were allowed to differentiate for 7 days before use. All plates were maintained at 37°C in 5% CO 2 and 95% air. For all axonal transport experiments, motoneurons were treated with 5 µM dihydrotestosterone (DHT) or vehicle for 3 days before transport assays were performed.
Measurement of axonal transport
Transport kinetics were analysed as described previously (18) . An atoxic fluorescent fragment of tetanus toxin (TeNT H C ) was used to visualise fast retrograde transport in cultured embryonic motoneurons from E13 WT and mutant AR100 mice. TeNT H C has been shown to bind with high affinity to the plasma membrane of neurons and can enter endocytic carriers containing neurotrophins and their receptors in motoneurons (19) . The
TeNT H C labelled endosome carriers can therefore be used in the monitoring of retrograde axonal transport (16). Fluorescent density of carriers was quantified using
Metamorph (Universal Imaging Corporation, Downingtown, PA).
In vivo retrograde transport assay in intact sciatic nerve
An in vivo transport assay was employed to test for axonal transport deficits in the sciatic nerve of symptomatic SBMA mice (16). 13-month old heterozygous AR100 mice and age-matched male WT littermates were anaesthetized with isoflurane (National Veterinary Services, Stoke-on-Trent, UK) and their tibialis anterior (TA) and gastrocnemius (GC) muscles exposed in one hindlimb. AlexaFluor555-TeNT H C (13 µg) and BDNF (50 ng), which has been reported to increase TeNT H C internalization (49),
were slowly injected intramuscularly using a Hamilton microsyringe as previously described (16) . The mice were re-anaesthetized 6 hours later and the sciatic nerve Tracking and data quantification
Tracking was undertaken using the Motion Analysis software (Kinetic Imaging, Liverpool, UK) as previously described (7, 16, 18) . Moving carriers that could be tracked for at least four consecutive time points were considered. The distance covered by a carrier between two consecutive frames (single movement) was used to determine speed.
The speed distribution of transport organelles from different mouse genotypes and age groups were obtained using a 0.2 µm/s binning interval.
Motoneuron survival
Motoneuron counts were performed as previously described (51 
Statistical analysis
Statistical analysis and curve fitting of axonal transport data were performed using Kaleidagraph (Synergy Software), Microsoft Excel and SPSS v15 (SPSS Inc) and as described previously (16) . Mean velocity of TeNT H C labelled endosome carriers was calculated using non-linear regression and tested for significance using a Student's t-test or ANOVA as described (16). Other statistical analysis was performed using SPSS v15.
To test for significance, non parametric data analysis was performed using the Kruskal- 
